MedTrace Logo

Phase 1 Trial of Ebola Vaccine in Mali

NCT02267109 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2019-09-26

No results posted yet for this study

Summary

Ebola virus causes an infection known as Ebola virus disease (EVD). This is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever. Researchers want to develop a vaccine to prevent Ebola infection. It is impossible for someone to get an Ebola infection from this vaccine.

Conditions

  • Ebola Virus Disease
  • Hemorrhagic Fever

Interventions

BIOLOGICAL

Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z

IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):

BIOLOGICAL

Booster-MVA-BN® Filo or saline placebo

IM injection of Booster-MVA-BN® Filo or saline placebo

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Leidos Biomedical Research, Inc.

    collaborator INDUSTRY

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Myron M Levine, MD, DTPH · University of Maryland, Baltimore

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-04-20
Completion
2016-04-20

Countries

  • Mali

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02267109 on ClinicalTrials.gov